JP2024509376A5 - - Google Patents

Info

Publication number
JP2024509376A5
JP2024509376A5 JP2023549551A JP2023549551A JP2024509376A5 JP 2024509376 A5 JP2024509376 A5 JP 2024509376A5 JP 2023549551 A JP2023549551 A JP 2023549551A JP 2023549551 A JP2023549551 A JP 2023549551A JP 2024509376 A5 JP2024509376 A5 JP 2024509376A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
cholesterol
days
derivative
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509376A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017090 external-priority patent/WO2022178318A1/en
Publication of JP2024509376A publication Critical patent/JP2024509376A/ja
Publication of JP2024509376A5 publication Critical patent/JP2024509376A5/ja
Pending legal-status Critical Current

Links

JP2023549551A 2021-02-18 2022-02-18 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法 Pending JP2024509376A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150908P 2021-02-18 2021-02-18
US63/150,908 2021-02-18
PCT/US2022/017090 WO2022178318A1 (en) 2021-02-18 2022-02-18 Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins

Publications (2)

Publication Number Publication Date
JP2024509376A JP2024509376A (ja) 2024-03-01
JP2024509376A5 true JP2024509376A5 (https=) 2025-02-27

Family

ID=82800248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549551A Pending JP2024509376A (ja) 2021-02-18 2022-02-18 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法

Country Status (5)

Country Link
US (2) US20220260597A1 (https=)
EP (1) EP4294403A4 (https=)
JP (1) JP2024509376A (https=)
AU (1) AU2022222756A1 (https=)
WO (1) WO2022178318A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024053812A1 (en) * 2022-09-08 2024-03-14 Renatus Inc. Methods for the treatment of chronic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
AU773385B2 (en) * 1999-05-14 2004-05-27 Esperion Luv Development, Inc. Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
WO2001055301A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2553710A1 (en) * 2004-01-15 2005-07-28 Aska Pharmaceutical Co., Ltd. Abca1 stabilizer
CA2737924A1 (en) * 2008-10-06 2010-04-15 Joshua Robert Schultz Methods of treating inflammation
WO2011116245A2 (en) * 2010-03-19 2011-09-22 Carolus Therapeutics, Inc. Methods of treating inflammation
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.
EP3405501B1 (en) * 2016-01-21 2023-11-15 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
CN107854448A (zh) * 2017-11-06 2018-03-30 广州市桐晖药业有限公司 一种烟酸片及其制备方法
EP3870181B1 (en) * 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
KR20230096975A (ko) * 2020-08-27 2023-06-30 베렌 테라퓨틱스 피.비.씨. 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법

Similar Documents

Publication Publication Date Title
JP6491089B2 (ja) シクロデキストリンを使用するための方法
JP2018203747A5 (https=)
JP5938394B2 (ja) 安定化スタチン製剤
JP2012528796A5 (https=)
US20220000824A1 (en) Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid
KR20120046125A (ko) 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체?매개 상실을 예측하는 방법 및 키트
JP2017509624A5 (https=)
JP6632999B2 (ja) 神経疾患および大脳損傷の処置のための組成物および方法
JP2024509376A5 (https=)
US20240209097A1 (en) Treatment regimens
Vuorio et al. Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
JP2021529766A5 (https=)
JP2024109841A (ja) 冠動脈疾患における積極的脂質低下療法
JP2021501793A (ja) 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法
Efthimiadis Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?
JP2022543084A (ja) リポソーム及びその使用
Skoczyńska et al. Postprandial lipemia in diabetic men during hypolipemic therapy
Wilkinson et al. * Real-World Experience with Inclisiran at a Large Academic Lipid Clinic
US20240425838A1 (en) TREATMENT OF ADVANCED IgA NEPHROPATHY
Jonas Häner et al. Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS)
Cabezas et al. Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies
CN101115480A (zh) 马尼地平和他汀类药物的治疗组合
Zannas Methylomic signatures mediate the effect of psychosocial stress on coronary heart disease
Lovell et al. SAT0489 PREVALENCE OF AUTOIMMUNE DISEASES IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS